LBPH vs. SCTL, ARWR, IDYA, PTCT, MOR, DYN, JANX, MLTX, TGTX, and RNA
Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Societal CDMO (SCTL), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), PTC Therapeutics (PTCT), MorphoSys (MOR), Dyne Therapeutics (DYN), Janux Therapeutics (JANX), MoonLake Immunotherapeutics (MLTX), TG Therapeutics (TGTX), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical preparations" industry.
Societal CDMO (NASDAQ:SCTL) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.
Longboard Pharmaceuticals has a net margin of 0.00% compared to Longboard Pharmaceuticals' net margin of -14.03%. Longboard Pharmaceuticals' return on equity of -23.82% beat Societal CDMO's return on equity.
Societal CDMO currently has a consensus target price of $1.80, suggesting a potential upside of 63.64%. Longboard Pharmaceuticals has a consensus target price of $43.67, suggesting a potential upside of 131.41%. Given Societal CDMO's stronger consensus rating and higher probable upside, analysts plainly believe Longboard Pharmaceuticals is more favorable than Societal CDMO.
87.2% of Societal CDMO shares are held by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are held by institutional investors. 7.6% of Societal CDMO shares are held by insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Societal CDMO has higher revenue and earnings than Longboard Pharmaceuticals. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Societal CDMO, indicating that it is currently the more affordable of the two stocks.
In the previous week, Longboard Pharmaceuticals had 4 more articles in the media than Societal CDMO. MarketBeat recorded 4 mentions for Longboard Pharmaceuticals and 0 mentions for Societal CDMO. Societal CDMO's average media sentiment score of 1.08 beat Longboard Pharmaceuticals' score of 0.00 indicating that Longboard Pharmaceuticals is being referred to more favorably in the news media.
Longboard Pharmaceuticals received 36 more outperform votes than Societal CDMO when rated by MarketBeat users. However, 80.00% of users gave Societal CDMO an outperform vote while only 73.33% of users gave Longboard Pharmaceuticals an outperform vote.
Societal CDMO has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Summary
Societal CDMO beats Longboard Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Longboard Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longboard Pharmaceuticals Competitors List
Related Companies and Tools
